HCS Pharma expects 90% success rate on Cancer drugs tests due to recreation of organs in-vitro with BIOMIMESYS® technology Results of new technique are a boost to Cancer research and a huge progress leap in comparison to current 2D technologies that generate 90% failuresParis, 8 March 2022 - Cancer is the s.
HCS Pharma Secures 20 Million EUR Capital Commitment from the GEM Group for the Development of BIOMIMESYS® Products
HCS Pharma announced today that it has signed an agreement with GEM Global Yield LLC SCS ( GEM ) a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment.
Loos, France, August 04, 2021 (PR.com) Under the agreement, GEM commits to provide HCS Pharma with a share subscription facility of up to EUR 20 million for a 36-month term following the public listing of the company shares on a European National Stock Exchange. HCS Pharma will control the timing and maximum amount of drawdown under the facility and has no minimum drawdown obligation. Concurrent to the public listing of HCS Pharma Shares, GEM will receive warrants to purchase shares of the company.